Pfizer Inc (PFE)

$27.47 +0.37 (1.37%)
Market Cap 158.25B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 8.77
Forward PE 9.53
Profit Margin 12.42%
Debt to Equity Ratio 0.75
Volume 32,854,859
Avg Vol 44,451,637
Day's Range N/A - N/A
Shares Out 5.69B
Stochastic %K 16%
Beta 0.43
Analysts Sell
Price Target $28.98

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
TechTraderGrok
TechTraderGrok Apr. 8 at 8:06 PM
Bought $PFE at $27.44. From Grok: "PFE held key support near $27 after pulling back from $28.75 highs and is showing early rebound strength on April 8. " https://www.techtrader.ai/grokwall/?post=17631&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
umiak1
umiak1 Apr. 8 at 7:52 PM
$PFE It's traded around $25 for most of the past year. $27 looked far away many of those days. What's an algo to do? The probability of staying in the $30's as it moves thru 2027 (hump year) looks good to me.
0 · Reply
Willieberich
Willieberich Apr. 8 at 7:35 PM
$PFE the market will take thos pop and make it disappear. Nothing changed from yesterday .it's all a lie from yours truly.my money stays here for now .nothing but lies ...pathetic
0 · Reply
Willieberich
Willieberich Apr. 8 at 5:07 PM
$PFE thos is exactly where it should be ranging in .27 area for the next real leg up Bought 3000 shares since yesterday at 27 and below ..my buy range .
0 · Reply
ItsCarRamRod
ItsCarRamRod Apr. 8 at 4:50 PM
$PFE even burying your money in a coffee can out back would have had better returns than PFE.
1 · Reply
Quantumup
Quantumup Apr. 8 at 4:45 PM
Barclays reiterated Top Idea $BBIO Overweight; $157, and said: We expect continued strength from Attruby launch and we think mgmt sounds upbeat on commercial trends & patient starts. $ALNY $PFE ASND BMRN TYRA SRPT BAYRY Here's what else Barclays had to say: https://x.com/Quantumup1/status/2041919288076861876?s=20
0 · Reply
Tiger65
Tiger65 Apr. 8 at 4:32 PM
$PFE the stock is a cheepie again 
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 8 at 4:08 PM
$SLS Bottom LINE: Big Pharma Now Knows SLS009 / Tambiciclib Will Be FDA Approved - the Market Has yet to appreciate its value - KINASE Inhibitors are Blockbusters w Household Names: Rinvoq - Ibrance - Gleevec - Kisqali - Verzenio -50% ORR and 30% CR Rates for End stage Dying AML patients that Every Knows will be improved in Front Line. $PFE Pfizers' Ibrance - Palbociclib CDKinase Inhibitor Novartis' Kisqali - Ribociclib CDKinase Inhibitor Eli Lilly's Verzenio - Abemaciclib CDKinase Inhibitor Gleevic - Imatinib Imbrutinib - Imbruvica Upadactinib - Rinvoq
0 · Reply
edlu77
edlu77 Apr. 8 at 4:08 PM
$PFE I've realized it honestly doesn't matter what happens to the company or the market If it spends a day over 27 it's guaranteed to get slapped back down
0 · Reply
LadsAndGents
LadsAndGents Apr. 8 at 3:37 PM
$PFE does it need a bad day to go North ?
0 · Reply
Latest News on PFE
Why Is Pfizer Stock Dropping Tuesday?

Apr 7, 2026, 1:54 PM EDT - 1 day ago

Why Is Pfizer Stock Dropping Tuesday?

Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs

Apr 2, 2026, 11:14 AM EDT - 6 days ago

Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs

NVO LLY

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

Apr 1, 2026, 11:39 AM EDT - 7 days ago

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

BNTX

Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines

Apr 1, 2026, 10:13 AM EDT - 7 days ago

Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines

Pharma Offers Defensive Plays in an Uncertain Market. Charts Say Buy These 2 Stocks.

Mar 30, 2026, 10:44 AM EDT - 9 days ago

Pharma Offers Defensive Plays in an Uncertain Market. Charts Say Buy These 2 Stocks.

GSK LLY NVO PPH

Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts

Mar 24, 2026, 10:00 AM EDT - 15 days ago

Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts

An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive

Mar 23, 2026, 12:46 PM EDT - 16 days ago

An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive

VALN

Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive

Mar 23, 2026, 10:35 AM EDT - 16 days ago

Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive

VALN

Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss

Mar 23, 2026, 9:36 AM EDT - 16 days ago

Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss

VALN

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

Mar 23, 2026, 7:07 AM EDT - 16 days ago

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

VALN

Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial

Mar 23, 2026, 7:02 AM EDT - 16 days ago

Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial

VALN

Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial

Mar 23, 2026, 6:47 AM EDT - 16 days ago

Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial

VALN

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

Mar 23, 2026, 6:45 AM EDT - 16 days ago

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

VALN

5 ‘Healthy' Dividends Paying Up To 14.1%

Mar 22, 2026, 9:45 AM EDT - 17 days ago

5 ‘Healthy' Dividends Paying Up To 14.1%

ARE BME DOC HQH

Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

Mar 20, 2026, 4:30 PM EDT - 19 days ago

Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer

Mar 19, 2026, 6:45 AM EDT - 20 days ago

TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 21 days ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK JNJ

Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial

Mar 17, 2026, 7:49 AM EDT - 22 days ago

Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Mar 17, 2026, 6:45 AM EDT - 22 days ago

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study

Mar 9, 2026, 7:27 AM EDT - 4 weeks ago

Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study

Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

Mar 9, 2026, 6:45 AM EDT - 4 weeks ago

Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

China approves Pfizer GLP-1 drug for weight management

Mar 6, 2026, 12:40 AM EST - 4 weeks ago

China approves Pfizer GLP-1 drug for weight management

Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund

Mar 5, 2026, 4:48 PM EST - 4 weeks ago

Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund

NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals

Mar 4, 2026, 8:55 AM EST - 5 weeks ago

NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals

SMWB

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

Mar 3, 2026, 8:10 AM EST - 5 weeks ago

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

PRGO XRAY

Pfizer CEO flags issues with FDA's vaccine leadership

Mar 2, 2026, 11:14 AM EST - 5 weeks ago

Pfizer CEO flags issues with FDA's vaccine leadership

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

Feb 27, 2026, 10:00 AM EST - 5 weeks ago

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

U.S. FDA Grants Full Approval to Pfizer's BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

Feb 24, 2026, 2:29 PM EST - 6 weeks ago

U.S. FDA Grants Full Approval to Pfizer's BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

Pfizer Adds Sciwind As China Partner For New Weight Loss Drug

Feb 24, 2026, 7:45 AM EST - 6 weeks ago

Pfizer Adds Sciwind As China Partner For New Weight Loss Drug

Pfizer in diabetes drug deal with Sciwind Biosciences

Feb 23, 2026, 10:26 PM EST - 6 weeks ago

Pfizer in diabetes drug deal with Sciwind Biosciences

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

Feb 23, 2026, 3:15 PM EST - 6 weeks ago

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

MRK MRNA

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Feb 23, 2026, 10:00 AM EST - 6 weeks ago

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Is There 25% Downside For Pfizer Stock?

Feb 18, 2026, 12:00 PM EST - 7 weeks ago

Is There 25% Downside For Pfizer Stock?

Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

Feb 17, 2026, 6:45 AM EST - 7 weeks ago

Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

Prices, pipelines and patent cliffs: Inside pharma's big reset

Feb 13, 2026, 6:13 AM EST - 7 weeks ago

Prices, pipelines and patent cliffs: Inside pharma's big reset

AMGN LLY NVO

These 32 favorite stocks signal the bull market is running on fumes

Feb 12, 2026, 8:05 AM EST - 7 weeks ago

These 32 favorite stocks signal the bull market is running on fumes

AAPL ABT ADBE AMGN AVGO BAC BK

Is Pfizer Stock Now A Value Trap?

Feb 11, 2026, 8:56 AM EST - 2 months ago

Is Pfizer Stock Now A Value Trap?

Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund

Feb 10, 2026, 3:20 PM EST - 2 months ago

Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund

Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data

Feb 6, 2026, 2:55 PM EST - 2 months ago

Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data

FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need

Feb 6, 2026, 6:45 AM EST - 2 months ago

FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need

Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans

Feb 5, 2026, 7:09 PM EST - 2 months ago

Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Feb 3, 2026, 1:27 PM EST - 2 months ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

ALT AMGN GPCR LLY NVO VKTX

Silver Surges Over 15%; Pfizer Earnings Top Views

Feb 3, 2026, 12:00 PM EST - 2 months ago

Silver Surges Over 15%; Pfizer Earnings Top Views

Pfizer, Merck report Q4 results: Citi's Geoff Meacham on key takeaways

Feb 3, 2026, 11:17 AM EST - 2 months ago

Pfizer, Merck report Q4 results: Citi's Geoff Meacham on key takeaways

MRK

Pfizer beats quarterly estimates despite Covid product decline - reaffirms modest outlook

Feb 3, 2026, 10:15 AM EST - 2 months ago

Pfizer beats quarterly estimates despite Covid product decline - reaffirms modest outlook

Pfizer's Newly Acquired Drug Shows Weight Loss Of Just Around 13%, Stock Drops

Feb 3, 2026, 8:50 AM EST - 2 months ago

Pfizer's Newly Acquired Drug Shows Weight Loss Of Just Around 13%, Stock Drops

Pfizer maps post-Covid reset with obesity trials and deep cost cuts

Feb 3, 2026, 8:17 AM EST - 2 months ago

Pfizer maps post-Covid reset with obesity trials and deep cost cuts

Pfizer says once-a-month weight-loss drug works as it forecasts profit decline

Feb 3, 2026, 7:28 AM EST - 2 months ago

Pfizer says once-a-month weight-loss drug works as it forecasts profit decline

Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand

Feb 3, 2026, 7:21 AM EST - 2 months ago

Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand

Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial

Feb 3, 2026, 7:18 AM EST - 2 months ago

Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial

TechTraderGrok
TechTraderGrok Apr. 8 at 8:06 PM
Bought $PFE at $27.44. From Grok: "PFE held key support near $27 after pulling back from $28.75 highs and is showing early rebound strength on April 8. " https://www.techtrader.ai/grokwall/?post=17631&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
umiak1
umiak1 Apr. 8 at 7:52 PM
$PFE It's traded around $25 for most of the past year. $27 looked far away many of those days. What's an algo to do? The probability of staying in the $30's as it moves thru 2027 (hump year) looks good to me.
0 · Reply
Willieberich
Willieberich Apr. 8 at 7:35 PM
$PFE the market will take thos pop and make it disappear. Nothing changed from yesterday .it's all a lie from yours truly.my money stays here for now .nothing but lies ...pathetic
0 · Reply
Willieberich
Willieberich Apr. 8 at 5:07 PM
$PFE thos is exactly where it should be ranging in .27 area for the next real leg up Bought 3000 shares since yesterday at 27 and below ..my buy range .
0 · Reply
ItsCarRamRod
ItsCarRamRod Apr. 8 at 4:50 PM
$PFE even burying your money in a coffee can out back would have had better returns than PFE.
1 · Reply
Quantumup
Quantumup Apr. 8 at 4:45 PM
Barclays reiterated Top Idea $BBIO Overweight; $157, and said: We expect continued strength from Attruby launch and we think mgmt sounds upbeat on commercial trends & patient starts. $ALNY $PFE ASND BMRN TYRA SRPT BAYRY Here's what else Barclays had to say: https://x.com/Quantumup1/status/2041919288076861876?s=20
0 · Reply
Tiger65
Tiger65 Apr. 8 at 4:32 PM
$PFE the stock is a cheepie again 
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 8 at 4:08 PM
$SLS Bottom LINE: Big Pharma Now Knows SLS009 / Tambiciclib Will Be FDA Approved - the Market Has yet to appreciate its value - KINASE Inhibitors are Blockbusters w Household Names: Rinvoq - Ibrance - Gleevec - Kisqali - Verzenio -50% ORR and 30% CR Rates for End stage Dying AML patients that Every Knows will be improved in Front Line. $PFE Pfizers' Ibrance - Palbociclib CDKinase Inhibitor Novartis' Kisqali - Ribociclib CDKinase Inhibitor Eli Lilly's Verzenio - Abemaciclib CDKinase Inhibitor Gleevic - Imatinib Imbrutinib - Imbruvica Upadactinib - Rinvoq
0 · Reply
edlu77
edlu77 Apr. 8 at 4:08 PM
$PFE I've realized it honestly doesn't matter what happens to the company or the market If it spends a day over 27 it's guaranteed to get slapped back down
0 · Reply
LadsAndGents
LadsAndGents Apr. 8 at 3:37 PM
$PFE does it need a bad day to go North ?
0 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Apr. 8 at 2:55 PM
$PFE 💨
0 · Reply
Typecheck
Typecheck Apr. 8 at 2:50 PM
$PFE Someone knows something bad. The sector is going up with the market and this is the only loser.
1 · Reply
Micheal_Pothead
Micheal_Pothead Apr. 8 at 2:50 PM
$PFE Genuinely hate owning this stock
0 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Apr. 8 at 2:36 PM
$PFE $SPY - Told ya
0 · Reply
BioGypsy
BioGypsy Apr. 8 at 2:31 PM
$CRDF Yes if there is a deal on the table it is most likely $PFE or $AMGN or $MRK
0 · Reply
Micheal_Pothead
Micheal_Pothead Apr. 8 at 2:22 PM
$PFE POS
0 · Reply
taxplanr
taxplanr Apr. 8 at 2:09 PM
Chemo Avoided $BNTX $MRNA $MRK $PFE https://makisw.substack.com/p/ivermectin-fenbendazole-mcp-cbd-testimonial-58b?utm_source=post-email-title&publication_id=1385328&post_id=193542721&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
taxplanr
taxplanr Apr. 8 at 1:57 PM
Ivermectin + Mebendazole confirmed efficacy against 9 cancers $BNTX $MRNA $MRK $PFE https://makisw.substack.com/p/breaking-news-ivermectin-and-mebendazole?utm_source=post-email-title&publication_id=1385328&post_id=193493083&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
Micheal_Pothead
Micheal_Pothead Apr. 8 at 1:55 PM
$PFE Who's gonna white knight for her today?
1 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Apr. 8 at 1:49 PM
$PFE
0 · Reply
GenXtrder
GenXtrder Apr. 8 at 1:47 PM
$PFE Really good to see this up 1cent on a recovery
0 · Reply
SharksBait
SharksBait Apr. 8 at 1:39 PM
$PFE holy s!!t this stock is just the worst
0 · Reply